… immediate growth driver in narcolepsy drug Lumryz.  But perhaps … commercialization of its own narcolepsy candidate, alixorexton. Under … dominant franchise in the narcolepsy market, Jazz Pharmaceuticals’ … combined sales of its narcolepsy duo at $833 million …

… therapy for sleep disorder narcolepsy that has been predicted … of the well-established narcolepsy drug sodium oxybate, which … daytime sleepiness associated with narcolepsy in 2023 and had … its in-house developed narcolepsy treatment alixorexton (formerly ALKS …

… 7 years of age with narcolepsy, to Alkermes’ commercial portfolio. This … over 50,000 oxybate-eligible narcolepsy patients in the United States …

… more than 3000 siblings without narcolepsy, to address familial confounding. … TAKEAWAY: Patients with narcolepsy had a higher lifetime prevalence … could not reliably distinguish between narcolepsy with and without cataplexy, and …

… acquiring Avadel Pharmaceuticals and its narcolepsy drug Lumryz in a deal … daytime sleepiness in adults with narcolepsy. About 3,100 U.S … also working on its own narcolepsy drug alixorexton, which, according to …

… or excessive daytime sleepiness in narcolepsy patients over seven years old … a Phase III programme in narcolepsy. “Avadel’s innovative portfolio, commercial …

… disorder (ADHD), the sleep disorder narcolepsy, or obesity. Commonly prescribed opioids … -Deficit Hyperactivity Disorder (ADHD) and narcolepsy—uncontrollable episodes of deep sleep …

… , not to be confused with narcolepsy, or necrophilia, although those are …

… symptom of one form of narcolepsy that’s characterized by a … have shown great promise in narcolepsy clinical trials, which has in … in the U.S. have narcolepsy. Analysts at the investment firm …

… where the condition differs from narcolepsy—where people need to sleep …